Cancer-treatment-induced bone loss, part 2

American Journal of Health-System Pharmacy

Volumn 63, Issue 6, 2006, Pages 534-546

  Michaud, Laura Boehnke ^a   Goodin, Susan ^b,c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Antineoplastic agents; Bisphosphonates; Bone diseases; Breast neoplasms; Calcitonin; Calcium; Calcium regulators; Diagnosis; Estrogens; Exercise; Hormones; Minerals; Nutrition; Orchiectomy; Prostatic neoplasms; Toxicity; Vitamin D; Vitamins

Indexed keywords

ALENDRONIC ACID; ANTINEOPLASTIC AGENT; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CHLORAMBUCIL; CLODRONIC ACID; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN; ETIDRONIC ACID; FLUOROURACIL; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; METHOTREXATE; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; PROGESTERONE; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE; UNINDEXED DRUG; VITAMIN D;

BEHAVIOR MODIFICATION; BONE DENSITOMETRY; BONE FRAGILITY; BONE MASS; BONE METASTASIS; BREAST CANCER; CALCIUM INTAKE; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER THERAPY; CASTRATION; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DIET; DRUG CONTRAINDICATION; EARLY CANCER; EARLY DIAGNOSIS; EXERCISE; FOLLOW UP; FRACTURE; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; HYPERCALCEMIA; HYPOGONADISM; LIFESTYLE; META ANALYSIS; METASTASIS; ORCHIECTOMY; OSTEOLYSIS; OSTEOPOROSIS; OSTEOSARCOMA; PATHOPHYSIOLOGY; PATIENT EDUCATION; PHARMACIST; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SYSTEMATIC REVIEW; VERTEBRA FRACTURE; VITAMIN INTAKE; WRIST FRACTURE;

EID: 33645073653     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp050045.p2     Document Type: Review

References (63)

1. Reid IR, Ames RW, Evans MC et al. Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial. Am J Med. 1995; 98:331-5.
2. 3 dietary supplementation on bone loss at the hip in men and women over the age of 60. J Clin Endocrinol Metab. 2000; 85:3011-9.
3. Heikinheimo RJ, Inkovaara JA, Harju EJ et al. Annual injection of vitamin D and fractures in aged bones. Calcif Tissue Int. 1992; 51:105-10.
4. Lips P, Graafmans WC, Ooms ME et al. Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial. Ann Intern Med. 1996; 124:400-6.
5. Dawson-Hughes B, Harris SS, Krall EA et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age and older. N Engl J Med. 1997; 337:670-6.
6. Gregg EW, Cauley JA, Seeley DG et al. Physical activity and osteoporotic fractures risk in older women. Ann Intern Med. 1998; 129:81-8.
7. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet. 2002; 359:2018-26.
8. Vincent KR, Braith RW. Resistance exercise and bone turnover in elderly men and women. Med Sci Sports Exerc. 2002; 34:17-23.
9. Ward KD, Klesges RC. A meta-analysis of the effects of cigarette smoking on bone mineral density. Calcif Tissue Int. 2001; 68:259-70.
10. Cesar-Nato JB, Benatti BB, Neto FH et al. Smoking cessation may present a positive impact on mandibular bone quality and periodontitis-related bone loss: a study in rats. J Periodontol. 2005; 76:520-5.
11. Waltman NL, Twiss JJ, Ott CD et al. Testing an intervention for preventing osteoporosis in postmenopausal breast cancer survivors. J Nurs Scholarsh. 2003; 35:333-8.
12. Powles TJ, McCloskey E, Paterson AH et al. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst. 1998; 90:704-8.
13. Rizzoli R, Forni M, Schaad MA et al. Effects of oral clodronate on bone mineral density in patients with relapsing breast cancer. Bone. 1996; 18:531-7.
14. Delmas PD, Balena R, Confravreux E et al. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol. 1997; 15:955-62.
15. Smith MR, Fallon MA, Lee H et al. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab. 2004; 89:3841-6.
16. Forteo (teriparatide) package insert. Indianapolis, IN: Eli Lilly and Co.; 2004 Sep.
17. O'Meara ES, Rossing MA, Daling JR et al. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst. 2001; 93:754-62.
18. Natrajan PK, Gambrell RD Jr. Estrogen replacement therapy in patients with early breast cancer. Am J Obstet Gynecol. 2002; 187:289-95.
19. Holmberg L, Anderson H, HABITS steering and data monitoring committees. HABITS (hormonal replacement therapy after breast cancer-is it safe?), a randomised comparison: trial stopped. Lancet. 2004; 363:453-5.
20. Chlebowski RT, Kim JA, Col NF. Estrogen deficiency symptom management in breast cancer survivors in the changing context of menopausal hormone therapy. Semin Oncol. 2003; 30:776-88.
21. Welnicka-Jaskiewicz M, Jassem J. The risks and benefits of hormonal replacement therapy in healthy women and in breast cancer survivors. Cancer Treat Rev. 2003; 29:355-61.
22. Taxel P, Fall PM, Albertsen PC et al. The effect of micronized estradiol on bone turnover and calciotropic hormones in older men receiving hormonal suppression therapy for prostate cancer. J Clin Endocrinol Metab. 2002; 87:4907-13.
23. Delmas PD, Fontana A. Bone loss induced by cancer treatment and its management. Eur J Cancer. 1998; 34:260-2.
24. Van Poznak C. How are bisphosphonates used today in breast cancer clinical practice? Semin Oncol. 2001; 28(4 suppl 11):69-74.
25. Ettinger B, Black DM, Mitlak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. 1999; 282:637-45.
26. O'Regan RM, Gajdos C, Dardes RC et al. Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice. J Natl Cancer Inst. 2002; 94:274-83.
27. Chesnut CH 3rd, Silverman S, Andriano K et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures study. Am J Med. 2000; 109:267-76.
28. Hosking D, Chilvers CE, Christiansen C et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med. 1998; 338:485-92.
29. McClung M, Clemmesen B, Daifotis A et al. Alendronate prevents postmenopausal bone loss in women with osteoporosis. A double-blind, randomized, controlled trial. Ann Intern Med. 1998; 128:253-61.
30. Fosamax (alendronate) package insert. Whitehouse Station, NJ: Merck & Co., Inc.; 2004 Apr.
31. Bone HG, Hosking D, Devogelaer JP et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004; 350:1189-99.
32. Orwoll E, Ettinger M, Weiss S et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000; 343:604-10.
33. Ringe JD, Dorst A, Faber H et al. Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol Int. 2004; 24:110-3.
34. Morabito N, Gaudio A, Lasco A et al. Three-year effectiveness of intravenous pamidronate versus pamidronate plus slow-release sodium fluoride for postmenopausal osteoporosis. Osteoporos Int. 2003; 14:500-6.
35. Thiébaud D, Burckhardt P, Melchior J et al. Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause. Osteoporos Int. 1994; 4:76-83.
36. Reid DM, Hughes RA, Laan RF et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J Bone Miner Res. 2000; 15:1006-13.
37. Reid DM, Adami S, Devogelaer JP et al. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int. 2001; 69:242-7.
38. Wallach S, Cohen S, Reid DM et al. Effects of risedronate treatment on bone density and vertebral fractures in patients on corticosteroid therapy. Calcif Tissue Int. 2000; 67:277-85.
39. Reginster JY, Minne HW, Sorensen OH et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int. 2000; 11:83-91.
40. Harris ST, Watts NB, Li Z et al. Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. Curr Med Res Opin. 2004; 20:757-64.
41. Harris ST, Watts NB, Genant HK et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA. 1999; 282:1344-52.
42. Reid IR, Brown JP, Burckhardt P et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002; 346:653-61.
43. USP DI Editorial Group. USP DI drug information for the health care professional. 24th ed. (electronic version). Taunton, MA: Micromedex, Inc.; 2004.
44. Ibandronate sodium. In: McEvoy GK, ed. AHFS drug information 2004 (electronic version). Bethesda, MD: American Society of Health-System Pharmacists; 2004.
45. Ruggiero SL, Mehrotra B, Rosenberg TJ et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004; 62:527-34.
46. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003; 61:1115-6. Letter.
47. Migliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol. 2003; 21:4253-4. Letter.
48. Tarassoff P, Csermak K. Avascular necrosis of the jaws: risk factors in metastatic cancer patients. J Oral Maxillofac Surg. 2003; 61:1238-9. Letter.
49. Food and Drug Administration. 2004 safety alerts for drugs, biologics, medical devices, and dietary supplements. www.fda.gov/medwatch/SAFETY/2004/ safety04.htm#zometa (accessed 2004 Oct 11).
50. Zometa (zoledronic acid) package insert. East Hanover, NJ: Novartis Pharmaceuticals Corp.; 2005 Apr.
51. Aredia (pamidronate) package insert. East Hanover, NJ: Novartis Pharmaceuticals Corp.; 2004 Aug.
52. Liberman UA, Weiss SR, Bröll J et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 1995; 333:1437-43.
53. Black DM, Cummings SR, Karpf DB et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996; 348:153-41.
54. Cummings SR, Black DM, Thompson DE et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998; 280:2077-82.
55. Saag KG, Emkey R, Schnitzer TJ et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med. 1998; 339:292-9.
56. Delmas PD, Recker RR, Chesnut CH 3rd et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int. 2004; 15:792-8.
57. Boniva (ibandronate) package insert. Nutley, NJ: Roche Pharmaceuticals; 2005 Mar.
58. McClung MR, Wasnich RD, Recker R et al. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis. J Bone Miner Res. 2004; 19:11-8.
59. Gnant M, Hausmaninger H, Samonigg H et al. Changes in bone mineral density caused by anastrozole or tamoxifen in combination with goserelin (± zoledronate) as adjuvant treatment for hormone receptor-positive premenopausal breast cancer: results of a randomized multicenter trial. Paper presented at San Antonio Breast Cancer Symposium. San Antonio, TX; 2002 Dec 11.
60. Conte P. Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist. 2004; 9(suppl 4):28-37.
61. Fleming T, ed. 2004 Red book. 108th ed. Montvale, NJ: Thomson PDR; 2004.
62. ClinicalTrials.gov. Information on clinical trials and human research studies. Osteoporosis results. www.clinicaltrials.gov/ct/gui/actionSearchAction? term=Osteoporosis (accessed 2004 Sep 22).
63. Wisconsin Physicians Service Insurance Corporation. Wisconsin Medical Policy index: bisphosphonate drug therapy. www.wpsic.com/medicare/policies/ wisconsin/index.shtml (2004 Sep 22).